The maturation of the AIDS virus requires a protease responsible for the cleavage of the gag polyprotein, the precursor of the core structural proteins. Thus, the protease is a promising target for the development of inhibitors therapeutically useful For the treatment of AIDS. The long term goal of this project is to aid in the design of HIV protease inhibitors by providing detailed structural information on HIV protease and protease/inhibitor complexes using NMR spectroscopy. Specifically, we plan to: 1) determine the NH exchange rates of bound peptide inhibitors and compare the amide N and H chemical shifts of the free and enzyme bound inhibitors using isotope-edited proton NMR techniques. 2) perform isotope-edited 2D NOE experiments of protease/inhibitor complexes using isotopically labeled inhibitors to obtain detailed information on inhibitor conformation and active site structure, 3) determine the complete three-dimensional structure of the protease and protease/inhibitor complexes using a variety of 2D and 30 NMR methods, 4) characterize the structure of protease mutants and other AIDS-associated retroviral proteases (e.g., HIV-2).

Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Abbott Laboratories
Department
Type
DUNS #
City
North Chicago
State
IL
Country
United States
Zip Code
60064
Horne, David J; Narita, Masahiro; Spitters, Christopher L et al. (2013) Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis 57:1473-82
Kageyama, S; Weinstein, J N; Shirasaka, T et al. (1992) In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother 36:926-33
Fesik, S W; Gampe Jr, R T; Eaton, H L et al. (1991) NMR studies of [U-13C]cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding. Biochemistry 30:6574-83
Rao, J K; Erickson, J W; Wlodawer, A (1991) Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry 30:4663-71
Kempf, D J; Marsh, K C; Paul, D A et al. (1991) Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 35:2209-14
Rittenhouse, J; Turon, M C; Helfrich, R J et al. (1990) Affinity purification of HIV-1 and HIV-2 proteases from recombinant E. coli strains using pepstatin-agarose. Biochem Biophys Res Commun 171:60-6
Erickson, J; Neidhart, D J; VanDrie, J et al. (1990) Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527-33
Eaton, H L; Austin, R E; Fesik, S W et al. (1989) NMR study of the possible interaction in solution of angiotensin II with a peptide encoded by angiotensin II complementary RNA. Proc Natl Acad Sci U S A 86:9767-9